G5 Article dissertation

Safety and efficacy of cardioversion of acute atrial fibrillation – the Fincv (Finnish cardioversion) study




AuthorsGrönberg Toni

Publishing placeTurku

Publication year2017

ISBN978-951-29-7064-3

eISBN978-951-29-7065-0

Web address http://urn.fi/URN:ISBN:978-951-29-7065-0

Self-archived copy’s web addresshttp://urn.fi/URN:ISBN:978-951-29-7065-0


Abstract

Background: The inherent risk of thromboembolism after cardioversion of atrial fibrillation with a duration of more than 48 hours is well established. However, the potential increased risk of these complications after cardioversion of recent-onset episodes of atrial fibrillation has been more controversial. Thus, the aim of this dissertation was to evaluate the safety and efficacy of cardioversion of acute (< 48 hours) atrial fibrillation. 

Methods: The FinCV study is a multicenter (n=3) retrospective study of 3143 patients who underwent 7660 cardioversions for acute atrial fibrillation. Of those procedures, 5362 were performed without, and 2298 with, anticoagulation protection. 

Results: The success rate of electrical cardioversions was 94.2%. After successful procedures, atrial fibrillation recurred in 17.3% of cases within 30 days. The rate of thromboembolic events (mainly ischemic strokes) was 0.7% in non-anticoagulated patients after successful cardioversion of acute atrial fibrillation. Significant independent predictors of these complications were old age, female sex, heart failure and diabetes, along with a cardioversion delay of 12 hours or longer. The risk of thromboembolism was as high as 9.8% in patients with both heart failure and diabetes. The incidence of thromboembolic complications also increased significantly from 0.4% in nonanticoagulated patients with CHA2DS2VASc score of ≤ 1 to 2.3% in those with a score of ≥ 5. Overall, the incidence of thromboembolism was significantly lower after cardioversions performed during anticoagulation (0.1% vs. 0.7%). Altogether, 0.9% of electrical cardioversions resulted in bradyarrhythmia, and 44.4% of those patients underwent pacemaker implantation later. 

Conclusions: The cardioversion of acute atrial fibrillation does not increase the risk of thromboembolism in anticoagulated patients. However, this risk is unacceptably high in non-anticoagulated patients with conventional risk factors for stroke. High CHA2DS2VASc score and a delay to cardioversion of 12 hours or longer are significant predictors of thromboembolism. Overall, electrical cardioversion is an effective procedure and immediate arrhythmic complications are rare after these procedures.



Last updated on 03/12/2024 01:10:10 PM